https://news.medxy.ai/zh/andes-hantavirus-study/Medxy AIzh2026-09-13T10:53:29-07:00安第斯病毒相关汉坦病毒心肺综合征重症救治需求与结局的演变：来自智利全国队列的研究 https://news.medxy.ai/ja/andes-virus-icu-trends/Medxy AIja2026-09-13T10:53:11-07:00アンデスウイルス関連ハンタウイルス心肺症候群における集中治療需要と転帰の変化：チリ全国コホートからの知見 https://news.medxy.ai/vi/andes-virus-cardiopulmonary-syndrome/Medxy AIvi2026-09-13T10:52:54-07:00Gánh nặng hồi sức tích cực và kết cục đang thay đổi ở hội chứng tim phổi do Andes virus: dữ liệu từ một đoàn hệ quốc gia Chile https://news.medxy.ai/evolving-critical-care-needs-and-outcomes-in-andes-virus-associated-hantavirus-cardiopulmonary-syndrome-insights-from-a-national-chilean-cohort/Medxy AIen2026-09-13T10:52:37-07:00Evolving Critical Care Needs and Outcomes in Andes Virus-Associated Hantavirus Cardiopulmonary Syndrome: Insights from a National Chilean Cohort https://news.medxy.ai/zh/pediatric-cardiac-failure/Medxy AIzh2026-09-13T10:51:56-07:00儿童急性心肺衰竭分子亚表型的快速免疫测定：临床意义与未来方向 https://news.medxy.ai/ja/pediatric-acute-cardiopulmonary-failure/Medxy AIja2026-09-13T10:51:34-07:00小児急性心肺不全における分子サブフェノタイピング：迅速免疫測定法の臨床的意義と今後の展望 https://news.medxy.ai/vi/rapid-immunoassay/Medxy AIvi2026-09-13T10:51:10-07:00Xét nghiệm miễn dịch nhanh cho phân tầng dưới kiểu hình phân tử trong suy hô hấp–tuần hoàn cấp ở trẻ em: ý nghĩa lâm sàng và định hướng tương lai https://news.medxy.ai/rapid-immunoassay-for-molecular-subphenotyping-in-pediatric-acute-cardiorespiratory-failure-clinical-implications-and-future-directions/Medxy AIen2026-09-13T10:50:48-07:00Rapid Immunoassay for Molecular Subphenotyping in Pediatric Acute Cardiorespiratory Failure: Clinical Implications and Future Directions https://news.medxy.ai/zh/us-child-mental-health-trends/Medxy AIzh2026-09-13T10:49:55-07:00美国儿童心理健康相关急诊就诊与儿科就诊量变化（2016—2022）：综合综述 https://news.medxy.ai/ja/pediatric-mental-health-us/Medxy AIja2026-09-13T10:49:29-07:00米国における小児メンタルヘルス関連救急外来受診と小児受診数の動向（2016～2022年）: 包括的レビュー https://news.medxy.ai/vi/pediatric-ed-mental-health/Medxy AIvi2026-09-13T10:49:03-07:00Gia tăng lượt khám cấp cứu vì sức khỏe tâm thần ở trẻ em tại Hoa Kỳ và vai trò của lưu lượng ED nhi khoa (2016–2022): Tổng quan toàn diện https://news.medxy.ai/childhood-mental-health-related-emergency-department-visits-and-pediatric-volume-dynamics-in-the-us-2016-2022-a-comprehensive-review/Medxy AIen2026-09-13T10:48:37-07:00Childhood Mental Health-Related Emergency Department Visits and Pediatric Volume Dynamics in the US (2016-2022): A Comprehensive Review https://news.medxy.ai/zh/hospital-network-impact/Medxy AIzh2026-09-13T10:47:37-07:0018家医院网络实施揭示：健康社会决定因素筛查的真实影响 https://news.medxy.ai/ja/health-social-screening/Medxy AIja2026-09-13T10:47:22-07:0018病院ネットワーク導入で見えた、健康の社会的決定要因スクリーニングの実際と臨床的意義 https://news.medxy.ai/vi/social-determinants-health-2/Medxy AIvi2026-09-13T10:47:01-07:00Sàng lọc các yếu tố xã hội quyết định sức khỏe: Những phát hiện từ triển khai tại mạng lưới 18 bệnh viện https://news.medxy.ai/unveiling-the-impact-of-social-determinants-of-health-screening-insights-from-an-18-hospital-network-implementation/Medxy AIen2026-09-13T10:46:40-07:00Unveiling the Impact of Social Determinants of Health Screening: Insights from an 18-Hospital Network Implementation https://news.medxy.ai/zh/menopause-hormone-therapy-cvd-risk/Medxy AIzh2026-09-13T10:45:56-07:00绝经激素治疗与中年女性血管舒缩症状相关的心血管风险：来自 SWAN 研究的启示 https://news.medxy.ai/ja/menopause-hormone-therapy-heart-risk/Medxy AIja2026-09-13T10:45:37-07:00閉経期ホルモン療法は中年女性の心血管リスクをどう変えるか：SWAN研究が示す血管運動症状との関連 https://news.medxy.ai/vi/menopause-hormone-therapy-cvd-risk-2/Medxy AIvi2026-09-13T10:45:16-07:00Liệu pháp hormone mãn kinh và nguy cơ tim mạch ở phụ nữ trung niên có triệu chứng vận mạch: Góc nhìn từ nghiên cứu SWAN https://news.medxy.ai/menopausal-hormone-therapy-and-cardiovascular-risk-in-midlife-women-with-vasomotor-symptoms-insights-from-the-swan-study/Medxy AIen2026-09-13T10:44:56-07:00Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women with Vasomotor Symptoms: Insights from the SWAN Study https://news.medxy.ai/zh/hemoglobin-mortality-risk/Medxy AIzh2026-09-13T10:44:07-07:00血红蛋白水平与死亡风险：来自英国大型队列研究的启示 https://news.medxy.ai/ja/hemoglobin-mortality-risk-3/Medxy AIja2026-09-13T10:43:48-07:00ヘモグロビン値と死亡リスク：英国大規模コホート研究が示す新たな知見 https://news.medxy.ai/vi/hemoglobin-mortality-risk-2/Medxy AIvi2026-09-13T10:43:30-07:00Nồng độ Hemoglobin và Nguy cơ Tử vong: Góc nhìn từ một Nghiên cứu Đoàn hệ Lớn tại Vương quốc Anh https://news.medxy.ai/hemoglobin-levels-and-mortality-risk-insights-from-a-large-uk-cohort-study/Medxy AIen2026-09-13T10:43:11-07:00Hemoglobin Levels and Mortality Risk: Insights from a Large UK Cohort Study https://news.medxy.ai/zh/bcma-car-t-bridge/Medxy AIzh2026-09-13T10:41:50-07:00优化复发/难治性多发性骨髓瘤 BCMA 靶向 CAR T 细胞治疗前的桥接治疗：一项真实世界多中心分析 https://news.medxy.ai/ja/bcma-car-t-therapy/Medxy AIja2026-09-13T10:41:31-07:00再発・難治性多発性骨髄腫におけるBCMA標的CAR-T療法前ブリッジング治療の最適化：リアルワールド多施設解析 https://news.medxy.ai/vi/car-t-therapy-optimization/Medxy AIvi2026-09-13T10:41:07-07:00Tối ưu hóa liệu pháp cầu nối trước điều trị CAR T hướng đích BCMA ở đa u tủy xương tái phát/kháng trị: Phân tích đa trung tâm trong thực hành thực tế https://news.medxy.ai/optimizing-bridging-therapy-before-bcma-directed-car-t-cell-treatment-in-relapsed-refractory-multiple-myeloma-a-real-world-multicenter-analysis/Medxy AIen2026-09-13T10:40:48-07:00Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis https://news.medxy.ai/zh/myeloproliferative-tumors-trends/Medxy AIzh2026-09-13T10:40:02-07:00骨髓增殖性肿瘤流行病学与生存趋势的演变：来自SEER 2000—2021年的观察 https://news.medxy.ai/ja/myeloproliferative-tumors/Medxy AIja2026-09-13T10:39:40-07:00骨髄増殖性腫瘍の疫学と生存の変遷：SEER 2000–2021からの知見 https://news.medxy.ai/vi/epigenetics-survival-trends/Medxy AIvi2026-09-13T10:39:17-07:00Dịch tễ học biến đổi và xu hướng sống còn trong nhóm tân sinh tăng sinh tủy: dữ liệu từ SEER giai đoạn 2000–2021 https://news.medxy.ai/evolving-epidemiology-and-survival-trends-in-myeloproliferative-neoplasms-insights-from-seer-2000-2021/Medxy AIen2026-09-13T10:38:54-07:00Evolving Epidemiology and Survival Trends in Myeloproliferative Neoplasms: Insights from SEER 2000-2021 https://news.medxy.ai/zh/prmt9-aml-resistance/Medxy AIzh2026-09-13T10:38:07-07:00靶向 PRMT9：破解 AML 中 Venetoclax 耐药的新策略 https://news.medxy.ai/ja/prmt9-targeting-aml/Medxy AIja2026-09-13T10:37:50-07:00AMLのベネトクラクス耐性を打破するPRMT9標的化――治療戦略を塗り替える可能性 https://news.medxy.ai/vi/72944-2/Medxy AIvi2026-09-13T10:37:30-07:00Nhắm đích PRMT9 để khắc phục tình trạng kháng Venetoclax trong bệnh bạch cầu cấp dòng tủy (AML): Một bước ngoặt trong chiến lược điều trị https://news.medxy.ai/targeting-prmt9-to-overcome-venetoclax-resistance-in-aml-a-paradigm-shift-in-therapeutic-strategy/Medxy AIen2026-09-13T10:37:10-07:00Targeting PRMT9 to Overcome Venetoclax Resistance in AML: A Paradigm Shift in Therapeutic Strategy https://news.medxy.ai/zh/72941-2/Medxy AIzh2026-09-13T10:36:30-07:00Astegolimab频繁急性加重的COPD的疗效与安全性研究：来自ALIENTO与ARNASA合并试验 https://news.medxy.ai/ja/copd-astegolimab/Medxy AIja2026-09-13T10:36:06-07:00頻回増悪を伴うCOPDに対するアステゴリマブ：ALIENTOおよびARNASA併合試験からの知見 https://news.medxy.ai/vi/astegolimab-copd-exacerbations/Medxy AIvi2026-09-13T10:35:40-07:00Astegolimab trong bệnh phổi tắc nghẽn mạn tính kịch phát thường xuyên: Góc nhìn từ phân tích gộp ALIENTO và ARNASA https://news.medxy.ai/astegolimab-for-chronic-obstructive-pulmonary-disease-with-frequent-exacerbations-insights-from-the-pooled-aliento-and-arnasa-trials/Medxy AIen2026-09-13T10:35:15-07:00Astegolimab for Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Insights from the Pooled ALIENTO and ARNASA Trials https://news.medxy.ai/zh/post-cataract-endophthalmitis/Medxy AIzh2026-09-13T10:34:08-07:00白内障术后眼内炎的微生物谱演变与临床特征：一项23年回顾性队列研究 https://news.medxy.ai/ja/72935-2/Medxy AIja2026-09-13T10:33:48-07:00白内障手術後眼内炎における微生物スペクトラムおよび臨床的特徴の変遷：23年間の後ろ向きコホート研究 https://news.medxy.ai/vi/endophthalmitis-post-cataract-surgery/Medxy AIvi2026-09-13T10:33:25-07:00Viêm nội nhãn sau phẫu thuật đục thủy tinh thể: Phổ vi sinh biến đổi và đặc điểm lâm sàng từ một nghiên cứu đoàn hệ hồi cứu kéo dài 23 năm https://news.medxy.ai/evolving-microbial-landscape-and-clinical-profiles-in-postcataract-endophthalmitis-insights-from-a-23-year-retrospective-cohort-study/Medxy AIen2026-09-13T10:33:02-07:00Evolving Microbial Landscape and Clinical Profiles in Postcataract Endophthalmitis: Insights from a 23-Year Retrospective Cohort Study https://news.medxy.ai/zh/hearing-aid-compliance/Medxy AIzh2026-09-13T10:32:14-07:00破解小耳畸形儿童骨导听力设备依从性难题 https://news.medxy.ai/ja/bone-conduction-hearing-aid-adherence/Medxy AIja2026-09-13T10:31:55-07:00小耳症児における骨導補聴器アドヒアランス低下の要因を探る https://news.medxy.ai/vi/bone-conduction-hearing-aids/Medxy AIvi2026-09-13T10:31:30-07:00Những yếu tố cản trở tuân thủ sử dụng thiết bị nghe dẫn truyền xương ở trẻ microtia https://news.medxy.ai/unraveling-adherence-challenges-to-bone-conduction-hearing-devices-in-pediatric-microtia-patients/Medxy AIen2026-09-13T10:31:10-07:00Unraveling Adherence Challenges to Bone Conduction Hearing Devices in Pediatric Microtia Patients https://news.medxy.ai/zh/liver-trauma-treatment/Medxy AIzh2026-09-13T10:30:31-07:00穿透性肝外伤：血管栓塞治疗与手术如何权衡生存获益和住院时长 https://news.medxy.ai/ja/arterial-embolization-surgery/Medxy AIja2026-09-13T10:30:12-07:00穿通性肝外傷における動脈塞栓術と手術：生存率と入院期間の最適なバランス https://news.medxy.ai/vi/angioembolization-vs-surgery/Medxy AIvi2026-09-13T10:29:50-07:00Angioembolization so với phẫu thuật trong chấn thương gan xuyên thấu: Cân bằng giữa sống còn và thời gian nằm viện https://news.medxy.ai/angioembolization-vs-surgery-in-penetrating-hepatic-trauma-balancing-survival-and-hospital-stay/Medxy AIen2026-09-13T10:29:31-07:00Angioembolization vs. Surgery in Penetrating Hepatic Trauma: Balancing Survival and Hospital Stay https://news.medxy.ai/zh/bridge-gap-transgender-care/Medxy AIzh2026-09-13T10:19:00-07:00缩小差距：提升意大利内分泌科医师在跨性别医疗中的能力 https://news.medxy.ai/ja/transgender-care-italy/Medxy AIja2026-09-13T10:18:44-07:00イタリアの内分泌専門医に求められるトランスジェンダー医療の知識と対応力の強化 https://news.medxy.ai/vi/transgender-healthcare-italy/Medxy AIvi2026-09-13T10:18:27-07:00Thu hẹp khoảng cách: Nâng cao năng lực chăm sóc sức khỏe người chuyển giới của các bác sĩ nội tiết Ý https://news.medxy.ai/bridging-the-gap-enhancing-italian-endocrinologists-competence-in-transgender-health-care/Medxy AIen2026-09-13T10:18:10-07:00Bridging the Gap: Enhancing Italian Endocrinologists’ Competence in Transgender Health Care https://news.medxy.ai/zh/thyroid-eye-disease-2/Medxy AIzh2026-09-13T10:17:37-07:00重新认识甲状腺眼病：为什么临床指标至关重要——聚焦 Innovate TED Initiative https://news.medxy.ai/ja/thyroid-eye-disease/Medxy AIja2026-09-13T10:17:21-07:00甲状腺眼症で臨床指標が重要な理由：Innovate TED Initiative の取り組みを読み解 https://news.medxy.ai/vi/thyroid-eye-index/Medxy AIvi2026-09-13T10:16:58-07:00Vì sao chỉ số đo lường lại quan trọng trong bệnh mắt tuyến giáp: Khám phá sáng kiến Innovate TED https://news.medxy.ai/why-metrics-matter-in-thyroid-eye-disease-exploring-the-innovate-ted-initiative/Medxy AIen2026-09-13T10:16:39-07:00Why Metrics Matter in Thyroid Eye Disease: Exploring the Innovate TED Initiative https://news.medxy.ai/widening-the-spectrum-of-disease-expression-due-to-heterozygous-variants-in-efemp1/Medxy AIen2026-09-13T10:16:06-07:00Widening the Spectrum of Disease Expression due to Heterozygous Variants in EFEMP1 https://news.medxy.ai/zh/bell-electrophysiology/Medxy AIzh2026-09-13T10:15:29-07:00Bell 麻痹预后评估再提升：超越 House-Brackmann 分级的电生理检查 https://news.medxy.ai/ja/bell-palsy-prognosis/Medxy AIja2026-09-13T10:15:04-07:00Bell麻痺の予後を高める：House-Brackmann分類を超える電気生理学的評価 https://news.medxy.ai/vi/electrophysiology-prediction/Medxy AIvi2026-09-13T10:14:45-07:00Liệt Bell: xét nghiệm điện sinh lý thần kinh giúp dự đoán tiên lượng chính xác hơn ngoài thang House-Brackmann https://news.medxy.ai/enhancing-prognosis-in-bell-palsy-electrodiagnostic-testing-beyond-house-brackmann-grade/Medxy AIen2026-09-13T10:14:25-07:00Enhancing Prognosis in Bell Palsy: Electrodiagnostic Testing Beyond House-Brackmann Grade https://news.medxy.ai/zh/pesticide-exposure-anosmia-2/Medxy AIzh2026-09-13T10:13:48-07:00高农药暴露事件与嗅觉功能障碍：来自农业队列的主客观证据整合 https://news.medxy.ai/ja/pesticide-exposure-olfactory-impairment/Medxy AIja2026-09-13T10:13:26-07:00高農薬曝露イベントと嗅覚機能障害：農業コホートからみた主観的・客観的エビデンスの統合 https://news.medxy.ai/vi/pesticide-exposure-anosmia/Medxy AIvi2026-09-13T10:12:58-07:00Phơi nhiễm thuốc trừ sâu mức cao và rối loạn khứu giác: Tích hợp bằng chứng chủ quan và khách quan từ các quần thể nông nghiệp https://news.medxy.ai/high-pesticide-exposure-events-and-olfactory-dysfunction-integrating-subjective-and-objective-evidence-from-agricultural-cohorts/Medxy AIen2026-09-13T10:12:37-07:00High Pesticide Exposure Events and Olfactory Dysfunction: Integrating Subjective and Objective Evidence from Agricultural Cohorts https://news.medxy.ai/ja/type1-diabetes-consensus/Medxy AIja2026-09-13T10:03:33-07:00一般集団への膵島自己抗体スクリーニング、早期1型糖尿病発見に向けた新国際コンセンサス https://news.medxy.ai/vi/international-consensus/Medxy AIvi2026-09-13T10:02:58-07:00Đồng thuận quốc tế mới: sàng lọc dân số chung bằng tự kháng thể đảo tụy để phát hiện đái tháo đường týp 1 giai đoạn sớm https://news.medxy.ai/zh/early-type1-diabetes/Medxy AIzh2026-09-13T10:02:25-07:00国际新共识：通过普通人群胰岛自身抗体筛查识别早期1型糖尿病 https://news.medxy.ai/new-international-consensus-screening-the-general-population-for-islet-autoantibodies-to-detect-early-stage-type-1-diabetes/Medxy AIen2026-09-13T10:01:59-07:00New International Consensus: Screening the General Population for Islet Autoantibodies to Detect Early-Stage Type 1 Diabetes https://news.medxy.ai/zh/teplizumab-type-1-diabetes-2/Medxy AIzh2026-09-13T10:00:44-07:00teplizumab可保留新诊断青少年1型糖尿病的β细胞功能：PROTECT试验按方案分析的新启示 https://news.medxy.ai/ja/teplizumab-type-1-diabetes/Medxy AIja2026-09-13T10:00:26-07:00テプリズマブは新規発症の小児1型糖尿病でβ細胞機能を守る：PROTECT試験PP解析から得られた知見 https://news.medxy.ai/vi/teplizumab-beta-cell-function/Medxy AIvi2026-09-13T10:00:08-07:00Teplizumab giúp bảo tồn chức năng tế bào beta ở người trẻ mới mắc đái tháo đường type 1: phân tích theo phác đồ từ thử nghiệm PROTECT https://news.medxy.ai/teplizumab-preserves-beta-cell-function-in-youth-with-newly-diagnosed-type-1-diabetes-insights-from-the-protect-trial-per-protocol-analysis/Medxy AIen2026-09-13T09:59:48-07:00Teplizumab Preserves Beta Cell Function in Youth with Newly Diagnosed Type 1 Diabetes: Insights from the PROTECT Trial Per-Protocol Analysis https://news.medxy.ai/zh/thyroxine-binding-protein/Medxy AIzh2026-09-13T09:59:11-07:00转甲状腺素蛋白心脏淀粉样变性的分子亚型：来自蛋白质组学分析与塔法米地疗效的启示 https://news.medxy.ai/ja/transthyretin-amyloidosis-2/Medxy AIja2026-09-13T09:58:54-07:00トランスサイレチン心アミロイドーシスの分子サブタイプ：プロテオミクス解析とタファミジス有効性から見えた新知見 https://news.medxy.ai/vi/transthyretin-amyloidosis-3/Medxy AIvi2026-09-13T09:58:33-07:00Các phân nhóm phân tử trong bệnh amyloidosis tim do transthyretin: Góc nhìn từ proteomics và hiệu quả của tafamidis https://news.medxy.ai/molecular-subtypes-in-transthyretin-cardiac-amyloidosis-insights-from-proteomics-profiling-and-tafamidis-efficacy/Medxy AIen2026-09-13T09:58:12-07:00Molecular Subtypes in Transthyretin Cardiac Amyloidosis: Insights from Proteomics Profiling and Tafamidis Efficacy https://news.medxy.ai/zh/adult-unilateral-deafness-implant/Medxy AIzh2026-09-13T09:57:34-07:00长期单侧耳聋成年人是否仍适合人工耳蜗植入？多中心研究带来新证据 https://news.medxy.ai/ja/cochlear-implant-study/Medxy AIja2026-09-13T09:57:16-07:00長期片側難聴の成人における人工内耳埋め込み術を再考する：多施設研究からのエビデンス https://news.medxy.ai/vi/cochlear-implant-adults-unilateral-deafness/Medxy AIvi2026-09-13T09:56:55-07:00Cấy ốc tai điện tử ở người lớn bị điếc một bên kéo dài: Bằng chứng từ nghiên cứu đa trung tâm https://news.medxy.ai/reevaluating-cochlear-implantation-in-adults-with-long-term-unilateral-deafness-evidence-from-a-multicenter-study/Medxy AIen2026-09-13T09:56:37-07:00Reevaluating Cochlear Implantation in Adults with Long-Term Unilateral Deafness: Evidence from a Multicenter Study https://news.medxy.ai/zh/wilms-tumor-survival-2/Medxy AIzh2026-09-13T09:56:01-07:00Wilms瘤淋巴结评估与生存结局：一项大型 COG 肾肿瘤研究的启示 https://news.medxy.ai/ja/wilms-tumor-lymph-node/Medxy AIja2026-09-13T09:55:44-07:00好組織型Wilms腫瘍におけるリンパ節評価と生存転帰：大規模COG腎腫瘍研究からの知見 https://news.medxy.ai/vi/wilms-tumor-survival/Medxy AIvi2026-09-13T09:55:24-07:00Đánh giá hạch bạch huyết và kết cục sống còn trong u Wilms mô học thuận lợi: Phát hiện từ một nghiên cứu lớn của COG về u thận https://news.medxy.ai/lymph-node-assessment-and-survival-outcomes-in-favorable-histology-wilms-tumor-insights-from-a-large-cog-renal-tumor-study/Medxy AIen2026-09-13T09:55:06-07:00Lymph Node Assessment and Survival Outcomes in Favorable Histology Wilms Tumor: Insights from a Large COG Renal Tumor Study https://news.medxy.ai/zh/pouchitis-antibiotic-challenges/Medxy AIzh2026-09-13T09:54:29-07:00pouchitis：抗生素短期有效，但菌株更替与毒力回归带来长期挑战 https://news.medxy.ai/ja/pouchitis-antibiotic-effects/Medxy AIja2026-09-13T09:54:13-07:00pouchitisにおける短期的な抗菌薬効果と長期的課題：微生物株動態と病原性再出現の示唆 https://news.medxy.ai/vi/antibiotic-challenges/Medxy AIvi2026-09-13T09:53:53-07:00Viêm túi chứa: kháng sinh giúp lui bệnh ngắn hạn nhưng còn nhiều thách thức lâu dài do tái nổi lên của chủng vi khuẩn và độc lực https://news.medxy.ai/short-term-antibiotic-success-but-long-term-challenges-in-pouchitis-insights-into-microbial-strain-dynamics-and-virulence-re-emergence/Medxy AIen2026-09-13T09:53:37-07:00Short-Term Antibiotic Success but Long-Term Challenges in Pouchitis: Insights into Microbial Strain Dynamics and Virulence Re-Emergence https://news.medxy.ai/zh/ptau217-apoe-cognitive-decline-2/Medxy AIzh2026-09-13T09:53:01-07:00血浆 p-tau217 联合 APOE 基因型：跨多族裔人群认知衰退风险预测的新策略 https://news.medxy.ai/ja/plasma-p-tau217-apoe-prediction/Medxy AIja2026-09-13T09:52:42-07:00多様な集団の認知機能低下予測に向けた血漿p-tau217とAPOE遺伝子型の統合 https://news.medxy.ai/vi/ptau217-apoe-cognitive-decline/Medxy AIvi2026-09-13T09:52:21-07:00Kết hợp p-tau217 huyết tương và kiểu gen APOE để dự đoán suy giảm nhận thức ở các quần thể đa dạng https://news.medxy.ai/integrating-plasma-p-tau217-and-apoe-genotype-to-predict-cognitive-decline-across-diverse-populations/Medxy AIen2026-09-13T09:52:01-07:00Integrating Plasma p-tau217 and APOE Genotype to Predict Cognitive Decline Across Diverse Populations https://news.medxy.ai/zh/immune-checkpoint-vegf-effects-2/Medxy AIzh2026-09-13T09:51:24-07:00免疫检查点与VEGF抑制剂的血管效应再认识：基于PET显像与免疫分型的研究 https://news.medxy.ai/ja/immune-checkpoint-vegf-effects/Medxy AIja2026-09-13T09:51:04-07:00免疫チェックポイント阻害薬とVEGF阻害薬が血管に及ぼす影響を読み解く：PET画像と免疫プロファイリングからの示唆 https://news.medxy.ai/vi/immune-checkpoint-vegf-impact/Medxy AIvi2026-09-13T09:50:43-07:00Giải mã tác động mạch máu của các thuốc ức chế điểm kiểm soát miễn dịch và VEGF: Góc nhìn từ PET và phân tích miễn dịch https://news.medxy.ai/unraveling-the-vascular-impact-of-immune-checkpoint-and-vegf-inhibitors-insights-from-pet-imaging-and-immune-profiling/Medxy AIen2026-09-13T09:50:23-07:00Unraveling the Vascular Impact of Immune Checkpoint and VEGF Inhibitors: Insights from PET Imaging and Immune Profiling https://news.medxy.ai/zh/liver-transplant-perfusion-comparison/Medxy AIzh2026-09-12T10:28:42-07:00肝移植中低温氧合灌注与常温机器灌注的真实世界结局比较 https://news.medxy.ai/ja/hypothermic-vs-normothermic-perfusion/Medxy AIja2026-09-12T10:28:23-07:00肝移植における低体温酸素化灌流と常温機械灌流の実臨床成績を比較する https://news.medxy.ai/vi/liver-transplant-blood-flow/Medxy AIvi2026-09-12T10:28:00-07:00So sánh kết cục thực tế của tưới máu ôxy hóa hạ thân nhiệt và tưới máu máy ở nhiệt độ bình thường trong ghép gan https://news.medxy.ai/comparative-real-world-outcomes-of-hypothermic-oxygenated-and-normothermic-machine-perfusion-in-liver-transplantation/Medxy AIen2026-09-12T10:27:41-07:00Comparative Real-World Outcomes of Hypothermic Oxygenated and Normothermic Machine Perfusion in Liver Transplantation https://news.medxy.ai/zh/dexamethasone-levels/Medxy AIzh2026-09-12T10:25:24-07:001 mg 过夜地塞米松抑制试验中血清地塞米松水平的决定因素：临床与药理学启示 https://news.medxy.ai/ja/dexamethasone-levels-3/Medxy AIja2026-09-12T10:25:02-07:001 mg夜間デキサメタゾン抑制試験における血清デキサメタゾン濃度の規定因子：臨床・薬理学的考察 https://news.medxy.ai/vi/dexamethasone-levels-2/Medxy AIvi2026-09-12T10:24:37-07:00Nồng độ dexamethasone huyết thanh trong nghiệm pháp ức chế dexamethasone qua đêm 1 mg: Những yếu tố quyết định và ý nghĩa lâm sàng https://news.medxy.ai/determinants-of-serum-dexamethasone-levels-during-the-1-mg-overnight-dexamethasone-suppression-test-clinical-and-pharmacological-insights/Medxy AIen2026-09-12T10:24:17-07:00Determinants of Serum Dexamethasone Levels During the 1-mg Overnight Dexamethasone Suppression Test: Clinical and Pharmacological Insights https://news.medxy.ai/zh/10khz-spinal-stimulation-2/Medxy AIzh2026-09-12T10:23:27-07:0010 kHz 高频脊髓刺激：推动疼痛性糖尿病周围神经病变的镇痛与感觉恢复 https://news.medxy.ai/ja/10khz-spinal-stimulation/Medxy AIja2026-09-12T10:23:05-07:0010 kHz高周波脊髄刺激で切り拓く疼痛性糖尿病性ニューロパチー治療：疼痛緩和と感覚回復の新展開 https://news.medxy.ai/vi/spinal-cord-stimulation-2/Medxy AIvi2026-09-12T10:22:40-07:00Kích thích tủy sống tần số cao 10 kHz: Bước tiến trong giảm đau và phục hồi cảm giác ở đau do bệnh thần kinh đái tháo đường https://news.medxy.ai/high-frequency-10-khz-spinal-cord-stimulation-advancing-pain-relief-and-sensory-recovery-in-painful-diabetic-neuropathy/Medxy AIen2026-09-12T10:22:20-07:00High-Frequency 10-kHz Spinal Cord Stimulation: Advancing Pain Relief and Sensory Recovery in Painful Diabetic Neuropathy https://news.medxy.ai/zh/tropical-cyclones-heart-disease/Medxy AIzh2026-09-12T10:21:22-07:00热带气旋与急性冠脉综合征：揭示中国大陆的心血管负担 https://news.medxy.ai/ja/tropical-storm-cardiovascular/Medxy AIja2026-09-12T10:21:05-07:00熱帯低気圧と急性冠症候群：中国本土における心血管負担を読み解く https://news.medxy.ai/vi/tropical-vortex-cardiac/Medxy AIvi2026-09-12T10:20:45-07:00Xoáy thuận nhiệt đới và hội chứng vành cấp: Làm rõ gánh nặng tim mạch tại Trung Quốc đại lục https://news.medxy.ai/tropical-cyclones-and-acute-coronary-syndromes-unraveling-the-cardiovascular-burden-in-mainland-china/Medxy AIen2026-09-12T10:20:26-07:00Tropical Cyclones and Acute Coronary Syndromes: Unraveling the Cardiovascular Burden in Mainland China https://news.medxy.ai/zh/gene-perspective-left-heart-failure/Medxy AIzh2026-09-12T10:19:45-07:00基因视角揭示左心发育不全综合征早发心衰风险：NC-DEFINE研究新发现 https://news.medxy.ai/ja/early-left-heart-failure-risk/Medxy AIja2026-09-12T10:19:27-07:00低形成左心症候群の早期心不全リスクをめぐる遺伝学的知見：NC-DEFINE研究の成果 https://news.medxy.ai/vi/left-heart-failure-risk/Medxy AIvi2026-09-12T10:19:06-07:00Phát hiện di truyền mới về nguy cơ suy tim sớm trong hội chứng thiểu sản tim trái: Kết quả từ nghiên cứu NC-DEFINE https://news.medxy.ai/genetic-insights-into-early-heart-failure-risk-in-hypoplastic-left-heart-syndrome-findings-from-the-nc-define-study/Medxy AIen2026-09-12T10:18:45-07:00Genetic Insights into Early Heart Failure Risk in Hypoplastic Left Heart Syndrome: Findings from the NC-DEFINE Study https://news.medxy.ai/zh/dilated-cardiomyopathy-genetics-2/Medxy AIzh2026-09-12T10:17:55-07:00扩张型心肌病遗传学版图再扩展：2024年全面再评估 https://news.medxy.ai/ja/72886-2/Medxy AIja2026-09-12T10:17:38-07:00拡張型心筋症における新たな展望：2024年における包括的な遺伝学的再評価 https://news.medxy.ai/vi/dilated-cardiomyopathy-genetics/Medxy AIvi2026-09-12T10:17:17-07:00Bệnh cơ tim giãn: Đánh giá lại toàn diện di truyền năm 2024 https://news.medxy.ai/expanding-horizons-in-dilated-cardiomyopathy-a-comprehensive-genetic-reassessment-in-2024/Medxy AIen2026-09-12T10:16:59-07:00Expanding Horizons in Dilated Cardiomyopathy: A Comprehensive Genetic Reassessment in 2024 https://news.medxy.ai/zh/s1p-trem2-axis/Medxy AIzh2026-09-12T10:09:31-07:00解密 S1P-TREM2 轴：驱动肝细胞癌免疫抑制性中性粒细胞与肿瘤进展的新型铁死亡抵抗机制 https://news.medxy.ai/ja/s1p-trem2-liver-cancer/Medxy AIja2026-09-12T10:09:08-07:00S1P-TREM2軸の解明：肝細胞癌における免疫抑制性好中球と腫瘍進展を駆動する新規フェロトーシス抵抗機構 https://news.medxy.ai/vi/72865-2/Medxy AIvi2026-09-12T10:08:46-07:00Trục S1P-TREM2 thúc đẩy các bạch cầu trung tính ức chế miễn dịch và sự tiến triển của khối u trong ung thư biểu mô tế bào gan https://news.medxy.ai/unraveling-the-s1p-trem2-axis-a-novel-ferroptosis-resistance-mechanism-driving-immunosuppressive-neutrophils-and-tumour-progression-in-hepatocellular-carcinoma/Medxy AIen2026-09-12T10:08:24-07:00Unraveling the S1P-TREM2 Axis: A Novel Ferroptosis-Resistance Mechanism Driving Immunosuppressive Neutrophils and Tumour Progression in Hepatocellular Carcinoma https://news.medxy.ai/zh/pregnancy-outcomes-leukemia/Medxy AIzh2026-09-12T10:05:40-07:00儿童与青少年急性白血病女性幸存者妊娠结局受何影响：HSCT预处理方案与常规化疗的比较 https://news.medxy.ai/ja/pediatric-leukemia-pregnancy/Medxy AIja2026-09-12T10:05:23-07:00小児・思春期急性白血病女性生存者における前処置レジメンが妊娠転帰へ及ぼす影響：HSCTと従来の化学療法の比較 https://news.medxy.ai/vi/conditioning-protocol-pregnancy/Medxy AIvi2026-09-12T10:05:03-07:00Ảnh hưởng của phác đồ điều kiện hóa đến kết cục thai kỳ ở nữ sống sót sau bệnh bạch cầu cấp tính thời thơ ấu và vị thành niên: HSCT so với hóa trị liệu thông thường https://news.medxy.ai/impact-of-conditioning-regimens-on-pregnancy-outcomes-in-female-survivors-of-childhood-and-adolescent-acute-leukemia-hsct-versus-conventional-chemotherapy/Medxy AIen2026-09-12T10:04:43-07:00Impact of Conditioning Regimens on Pregnancy Outcomes in Female Survivors of Childhood and Adolescent Acute Leukemia: HSCT versus Conventional Chemotherapy https://news.medxy.ai/zh/aml-transplantation-outcomes/Medxy AIzh2026-09-12T10:03:58-07:00AML异基因移植中，诱导疗程数与移植后环磷酰胺结局的关系 https://news.medxy.ai/ja/aml-remission-cycles-impact/Medxy AIja2026-09-12T10:03:38-07:00AMLにおける寛解導入回数は移植成績に影響するか――PTCy併用同種造血幹細胞移植の検討 https://news.medxy.ai/vi/chemo-cycles-aml/Medxy AIvi2026-09-12T10:03:14-07:00Ảnh hưởng của số đợt hóa trị tấn công đến kết cục ghép tế bào gốc dị sinh có cyclophosphamide sau ghép trong AML https://news.medxy.ai/impact-of-induction-course-number-on-outcomes-of-allogeneic-stem-cell-transplant-with-post-transplant-cyclophosphamide-in-aml/Medxy AIen2026-09-12T10:02:55-07:00Impact of Induction Course Number on Outcomes of Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide in AML https://news.medxy.ai/zh/tp53-leukemia-treatment/Medxy AIzh2026-09-12T09:58:40-07:00TP53 突变急性髓系白血病中阿扎胞苷与地西他滨疗效比较：来自 COMMAND 登记研究的启示 https://news.medxy.ai/ja/tp53-aml-treatment-comparison/Medxy AIja2026-09-12T09:58:21-07:00TP53変異AMLにおけるアザシチジンとデシタビンの比較有効性：COMMANDレジストリから見えた知見 https://news.medxy.ai/vi/azacitidine-decitabine-aml-tp53/Medxy AIvi2026-09-12T09:58:00-07:00Azacitidine và decitabine trong AML đột biến TP53: So sánh hiệu quả từ cơ sở dữ liệu COMMAND https://news.medxy.ai/comparative-effectiveness-of-azacitidine-and-decitabine-in-tp53-mutant-acute-myeloid-leukemia-insights-from-the-command-registry/Medxy AIen2026-09-12T09:57:39-07:00Comparative Effectiveness of Azacitidine and Decitabine in TP53-Mutant Acute Myeloid Leukemia: Insights from the COMMAND Registry https://news.medxy.ai/zh/multiple-myeloma-risk/Medxy AIzh2026-09-12T09:56:58-07:00新诊断多发性骨髓瘤风险分层再优化：循环肿瘤细胞识别 IMS-IMWG 2025 分期中的播散性基因组高危表型 https://news.medxy.ai/ja/multiple-myeloma-risk-2/Medxy AIja2026-09-12T09:56:40-07:00新規診断多発性骨髄腫のリスク層別化をさらに洗練する：循環腫瘍細胞が IMS-IMWG 2025 病期分類における播種性ゲノム高リスク表現型を同定 https://news.medxy.ai/vi/risk-stratification-myeloma/Medxy AIvi2026-09-12T09:56:20-07:00Tinh chỉnh phân tầng nguy cơ ở đa u tủy mới chẩn đoán: tế bào u tuần hoàn giúp nhận diện kiểu hình nguy cơ cao về bộ gen có tính lan tràn trong hệ thống phân giai đoạn IMS-IMWG 2025 https://news.medxy.ai/refining-risk-stratification-in-newly-diagnosed-multiple-myeloma-circulating-tumor-cells-identify-a-disseminated-genomic-high-risk-phenotype-within-ims-imwg-2025-staging/Medxy AIen2026-09-12T09:55:59-07:00Refining Risk Stratification in Newly Diagnosed Multiple Myeloma: Circulating Tumor Cells Identify a Disseminated Genomic High-Risk Phenotype Within IMS-IMWG 2025 Staging https://news.medxy.ai/zh/il-16-lymphoma-resistance/Medxy AIzh2026-09-12T09:55:12-07:00IL-16介导的B细胞淋巴瘤耐药机制：BTK抑制剂与R-CHOP失效的分子基础及治疗启示 https://news.medxy.ai/ja/btk-resistance-mechanism/Medxy AIja2026-09-12T09:54:53-07:00B細胞リンパ腫におけるBTK阻害薬・R-CHOP抵抗性の新たな機序：IL-16産生が担う役割と治療戦略 https://news.medxy.ai/vi/il-16-drug-resistance/Medxy AIvi2026-09-12T09:54:33-07:00IL-16 tạo ra cơ chế kháng thuốc với chất ức chế BTK và R-CHOP trong u lympho tế bào B: hiểu biết cơ chế và ý nghĩa điều trị https://news.medxy.ai/il-16-production-as-a-mechanism-of-resistance-to-btk-inhibitors-and-r-chop-in-b-cell-lymphomas-mechanistic-insights-and-therapeutic-implications/Medxy AIen2026-09-12T09:54:11-07:00IL-16 Production as a Mechanism of Resistance to BTK Inhibitors and R-CHOP in B-Cell Lymphomas: Mechanistic Insights and Therapeutic Implications https://news.medxy.ai/zh/arlocabtagene-autoleucel-multiple-myeloma/Medxy AIzh2026-09-12T09:53:17-07:00Arlocabtagene Autoleucel：为多线治疗后的复发/难治性多发性骨髓瘤带来新的治疗思路 https://news.medxy.ai/ja/arlocabtagene-multiple-myeloma/Medxy AIja2026-09-12T09:52:59-07:00重前治療例の再発・難治性多発性骨髄腫に挑むArlocabtagene Autoleucel：治療パラダイムを変える可能性 https://news.medxy.ai/vi/72790-2/Medxy AIvi2026-09-12T09:52:38-07:00Arlocabtagene Autoleucel: Một phương pháp điều trị mới cho đa u tủy xương tái phát/kháng trị sau nhiều đợt điều trị https://news.medxy.ai/arlocabtagene-autoleucel-advancing-treatment-paradigms-in-heavily-pretreated-relapsed-refractory-multiple-myeloma/Medxy AIen2026-09-12T09:52:18-07:00Arlocabtagene Autoleucel: Advancing Treatment Paradigms in Heavily Pretreated Relapsed/Refractory Multiple Myeloma https://news.medxy.ai/zh/chronic-critical-care-goals/Medxy AIzh2026-09-12T09:51:31-07:00慢性危重症中治疗目标的医师心智模型：对共享决策的启示 https://news.medxy.ai/ja/chronic-disease-treatment-goals/Medxy AIja2026-09-12T09:51:10-07:00慢性重症疾患における治療目標をめぐる医師のメンタルモデルを読み解く――共同意思決定への示唆 https://news.medxy.ai/vi/doctor-mental-models/Medxy AIvi2026-09-12T09:50:48-07:00Hiểu mô hình tinh thần của bác sĩ về mục tiêu chăm sóc trong bệnh nặng mạn tính: Hàm ý cho ra quyết định chung https://news.medxy.ai/physicians-goals-care/Medxy AIen2026-09-12T09:50:25-07:00Understanding Physicians’ Mental Models on Goals of Care in Chronic Critical Illness: Implications for Shared Decision Making https://news.medxy.ai/zh/tezepelumab-asthma-study-3/Medxy AIzh2026-09-12T09:49:43-07:00Tezepelumab 在多种重度哮喘表型中均展现出稳健的疗效与安全性：来自 4 期 PASSAGE 研究的启示 https://news.medxy.ai/ja/tezepelumab-asthma-effectiveness/Medxy AIja2026-09-12T09:49:23-07:00多様な重症喘息表現型におけるテゼペルマブの有効性・安全性を検証：第4相PASSAGE試験の知見 https://news.medxy.ai/vi/tezepelumab-efficacy-safety/Medxy AIvi2026-09-12T09:48:59-07:00Tezepelumab cho thấy hiệu quả và độ an toàn vượt trội trên nhiều kiểu hình hen nặng: Góc nhìn từ nghiên cứu PASSAGE pha 4 https://news.medxy.ai/tezepelumab-demonstrates-robust-efficacy-and-safety-across-diverse-severe-asthma-phenotypes-insights-from-the-phase-4-passage-study/Medxy AIen2026-09-12T09:48:38-07:00Tezepelumab Demonstrates Robust Efficacy and Safety Across Diverse Severe Asthma Phenotypes: Insights from the Phase 4 PASSAGE Study https://news.medxy.ai/zh/dupilumab-copd-benefits-2/Medxy AIzh2026-09-12T09:47:53-07:00Dupilumab 降低 COPD 急性加重、急诊就诊与糖皮质激素使用：来自 3 期合并分析的研究启示 https://news.medxy.ai/ja/72768-2/Medxy AIja2026-09-12T09:47:36-07:00デュピルマブはCOPDの増悪、救急外来受診、および糖質コルチコイド使用を減少させる https://news.medxy.ai/vi/dupilumab-copd-benefits/Medxy AIvi2026-09-12T09:47:17-07:00Dupilumab giúp giảm đợt cấp COPD, lượt khám cấp cứu và sử dụng corticosteroid: Kết quả từ phân tích gộp giai đoạn 3 https://news.medxy.ai/efficacy-of-dupilumab-in-reducing-copd-exacerbations-emergency-department-visits-and-corticosteroid-use-insights-from-a-pooled-phase-3-analysis/Medxy AIen2026-09-12T09:46:57-07:00Efficacy of Dupilumab in Reducing COPD Exacerbations, Emergency Department Visits, and Corticosteroid Use: Insights from a Pooled Phase 3 Analysis https://news.medxy.ai/zh/retinal-sensitivity-impacts/Medxy AIzh2026-09-12T09:46:11-07:00中间期年龄相关性黄斑变性中不同亚型网状假性玻璃膜疣对视网膜敏感度的差异影响 https://news.medxy.ai/ja/retinal-sensitivity-macular-degeneration/Medxy AIja2026-09-12T09:45:50-07:00中間期加齢黄斑変性における網状偽ドルーゼン亜型が網膜感度に及ぼす影響の違い https://news.medxy.ai/vi/reticular-pseudodrusen-effects/Medxy AIvi2026-09-12T09:45:28-07:00Phân nhóm reticular pseudodrusen ảnh hưởng khác nhau đến độ nhạy cảm võng mạc trong thoái hóa hoàng điểm liên quan tuổi giai đoạn trung gian https://news.medxy.ai/differential-impact-of-reticular-pseudodrusen-subtypes-on-retinal-sensitivity-in-intermediate-age-related-macular-degeneration/Medxy AIen2026-09-12T09:45:07-07:00Differential Impact of Reticular Pseudodrusen Subtypes on Retinal Sensitivity in Intermediate Age-Related Macular Degeneration https://news.medxy.ai/zh/dupilumab-atopic-dermatitis-eye/Medxy AIzh2026-09-12T09:44:23-07:00dupilumab治疗特应性皮炎相关眼表疾病：来自大型前瞻性 BioDay 队列的研究发现 https://news.medxy.ai/ja/dupilumab-eye-conditions/Medxy AIja2026-09-12T09:44:04-07:00アトピー性皮膚炎におけるdupilumab関連眼表面疾患を読み解く：BioDay大規模前向きコホートからの知見 https://news.medxy.ai/vi/dupilumab-eye-disease/Medxy AIvi2026-09-12T09:43:43-07:00Dupilumab và bệnh lý bề mặt nhãn cầu trong viêm da cơ địa: phát hiện từ đoàn hệ tiến cứu BioDay quy mô lớn https://news.medxy.ai/unveiling-dupilumab-associated-ocular-surface-disease-in-atopic-dermatitis-insights-from-a-large-prospective-bioday-cohort/Medxy AIen2026-09-12T09:43:24-07:00Unveiling Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis: Insights from a Large Prospective BioDay Cohort https://news.medxy.ai/zh/satralizumab-thyroid-eye-disease/Medxy AIzh2026-09-12T09:42:46-07:00Satralizumab 在甲状腺眼病治疗中展现出良好疗效与安全性：来自 SatraGO-1 和 SatraGO-2 Ⅲ期试验的启示 https://news.medxy.ai/ja/satralizumab-thyroid-eye-disease-2/Medxy AIja2026-09-12T09:42:26-07:00甲状腺眼症に対するsatralizumab、第3相試験で有望な有効性と安全性を示す https://news.medxy.ai/vi/satralizumab-eye-treatment/Medxy AIvi2026-09-12T09:42:03-07:00Satralizumab cho thấy hiệu quả và độ an toàn đầy hứa hẹn trong điều trị bệnh mắt tuyến giáp: Góc nhìn từ các thử nghiệm pha 3 SatraGO-1 và SatraGO-2 https://news.medxy.ai/satralizumab-demonstrates-promising-efficacy-and-safety-in-treating-thyroid-eye-disease-insights-from-phase-3-satrago-1-and-satrago-2-trials/Medxy AIen2026-09-12T09:41:42-07:00Satralizumab Demonstrates Promising Efficacy and Safety in Treating Thyroid Eye Disease: Insights from Phase 3 SatraGO-1 and SatraGO-2 Trials https://news.medxy.ai/ja/vocal-fatigue-vaping/Medxy AIja2026-09-12T09:40:52-07:00電子たばこ使用者における音声疲労の有病率と口腔乾燥症との関連 https://news.medxy.ai/vi/vocal-fatigue-vapers/Medxy AIvi2026-09-12T09:40:29-07:00Mệt mỏi giọng nói ở người hút thuốc lá điện tử và mối liên hệ với khô miệng https://news.medxy.ai/prevalence-of-voice-fatigue-and-its-correlation-with-xerostomia-in-e-cigarette-smokers/Medxy AIen2026-09-12T09:40:09-07:00Prevalence of Voice Fatigue and Its Correlation With Xerostomia in E-Cigarette Smokers https://news.medxy.ai/zh/child-nose-battery-removal/Medxy AIzh2026-09-12T09:39:07-07:00儿童鼻腔纽扣电池与磁铁取出后的长期结局及生活质量 https://news.medxy.ai/ja/long-term-outcome-pediatric-battery-removal/Medxy AIja2026-09-12T09:38:51-07:00小児の鼻腔内ボタン電池・磁石摘出後の長期転帰と生活の質 https://news.medxy.ai/vi/long-term-outcome-children/Medxy AIvi2026-09-12T09:38:31-07:00Kết cục lâu dài và chất lượng cuộc sống ở trẻ em sau khi lấy bỏ pin cúc áo và nam châm trong mũi https://news.medxy.ai/zh/cardiovascular-outcomes-cloning/Medxy AIzh2026-09-12T09:38:21-07:00克隆性造血中的心血管结局试验设计：精准医学的迫切任务 https://news.medxy.ai/long-term-outcomes-and-quality-of-life-in-children-following-nasal-button-battery-and-magnet-removal/Medxy AIen2026-09-12T09:38:13-07:00Long-Term Outcomes and Quality of Life in Children Following Nasal Button Battery and Magnet Removal https://news.medxy.ai/ja/cardiovascular-outcome-trial/Medxy AIja2026-09-12T09:38:04-07:00クローン性造血における心血管アウトカム試験の設計：精密医療に向けた必須課題 https://news.medxy.ai/vi/cardiovascular-trial-design/Medxy AIvi2026-09-12T09:37:42-07:00Thiết kế thử nghiệm kết cục tim mạch trong tạo huyết dòng vô định tiềm năng: Yêu cầu cấp thiết của y học chính xác https://news.medxy.ai/zh/us-robotic-vs-laparoscopic-cholecystectomy/Medxy AIzh2026-09-12T09:37:32-07:00美国机器人、腹腔镜与开腹胆囊切除术早期结局比较：全国性分析 https://news.medxy.ai/ja/robotic-laparoscopic-cholecystectomy/Medxy AIja2026-09-12T09:37:12-07:00米国におけるロボット・腹腔鏡・開腹胆嚢摘出術の早期成績を比較：全国解析 https://news.medxy.ai/vi/robotic-gallbladder-surgery/Medxy AIvi2026-09-12T09:36:45-07:00Đánh giá kết cục sớm của cắt túi mật hỗ trợ robot so với nội soi và phẫu thuật mở tại Hoa Kỳ: Phân tích trên toàn quốc https://news.medxy.ai/evaluating-early-outcomes-of-robotic-versus-laparoscopic-and-open-cholecystectomy-in-the-us-a-nationwide-analysis/Medxy AIen2026-09-12T09:36:24-07:00Evaluating Early Outcomes of Robotic versus Laparoscopic and Open Cholecystectomy in the US: A Nationwide Analysis https://news.medxy.ai/zh/ptsd-risk-prediction/Medxy AIzh2026-09-12T09:35:34-07:00枪伤幸存者 PTSD 风险预测：休克指数、低血压与输血的作用 https://news.medxy.ai/ja/ptsd-prediction-gunshot/Medxy AIja2026-09-12T09:35:17-07:00銃創生存者のPTSDを予測するには？ ショックインデックス・低血圧・輸血の役割 https://news.medxy.ai/vi/ptsd-prediction-survivors/Medxy AIvi2026-09-12T09:34:51-07:00Dự đoán PTSD ở người sống sót sau vết thương do súng bắn: Vai trò của chỉ số sốc, hạ huyết áp và truyền máu https://news.medxy.ai/predicting-ptsd-in-gunshot-wound-survivors-the-role-of-shock-index-hypotension-and-blood-transfusion/Medxy AIen2026-09-12T09:34:30-07:00Predicting PTSD in Gunshot Wound Survivors: The Role of Shock Index, Hypotension, and Blood Transfusion